This regulatory roundup focuses on the FDA, USDA and the FTC, as well as various state requirements for regulating CBD and other wellness products. We discuss regulatory and enforcement priorities prior to the outbreak of COVID-19 and how those may have changed—at least for the near term. In this webinar, we examine the federal/state divide, possible new priorities and the multitude of issues they present.
This webinar is part of a series focused on the litigation, regulatory and transactional considerations of the rapidly growing wellness product industry in the United States. Join us for our future sessions in September and December of 2020.
One hour of CA, NJ and NY CLE credit is pending for each session. Additional details to follow.
Originally published May 12, 2020.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.